Nicastrin Regulates Cutaneous Squamous Cell Carcinoma Progression Through the MAPK / ERK Signalling
Experimental Dermatology · 2026
DOI: 10.1111/exd.70350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Dermatology, 2026. Verfasst von Shumeng Xue und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking …. Hauptthemen laut MEDLINE: Skin Neoplasms, MAP Kinase Signaling System, Carcinoma, Squamous Cell. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the National Natural Science Foundation of China, Key Program of the Research Foundation of Jiangsu Commission of Health.
Abstract (Originalsprache)
Cutaneous squamous cell carcinoma (cSCC) is among the most common epithelial malignancies. Although cSCC arising in long‐standing acne inversa (AI) lesions is rare, it is a severe and clinically important complication of AI. Approximately one‐third of patients with AI harbour loss‐of‐function mutations in NCSTN . Whether NCSTN loss contributes to cSCC development remains unclear. To address this, we first examined its expression pattern in cSCC tissues. Interestingly, NCSTN expression was significantly decreased in cSCC tissues by immunohistochemistry (IHC) and Western blotting. Furthermore, loss of NCSTN promoted cSCC cell proliferation and migration in vitro and tumour growth in vivo. Proteomic analysis revealed that NCSTN deficiency promoted cell proliferation through activation of the MAPK/ERK signalling pathway, accompanied by reduced CLDN3 expression and alterations in cell‐adhesion‐related pathways. To validate the functional relevance of this signalling axis in vivo, we treated NCSTN‐knockdown tumour‐bearing mice with the ERK inhibitor SCH772984, which effectively suppressed tumour growth. Collectively, these findings demonstrate that loss of NCSTN drives cSCC progression through activation of MAPK/ERK signalling, and identify ERK signalling as a potential therapeutic vulnerability in NCSTN‐deficient cSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
- Department of Dermatology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Shumeng Xue, Yuanxing Shen, Chong Zhang, Qian Ye, Haoxiang Xu, Yanyan He
Förderung
- the National Natural Science Foundation of China
- Key Program of the Research Foundation of Jiangsu Commission of Health
Zitieren
APA
Xue, S., Shen, Y., Zhang, C., Ye, Q., Zhang, Y., Xu, H., & He, Y. (2026). Nicastrin Regulates Cutaneous Squamous Cell Carcinoma Progression Through the MAPK / ERK Signalling. Experimental Dermatology. https://doi.org/10.1111/exd.70350
Vancouver
Xue S, Shen Y, Zhang C, Ye Q, Zhang Y, Xu H, et al. Nicastrin Regulates Cutaneous Squamous Cell Carcinoma Progression Through the MAPK / ERK Signalling. Experimental Dermatology. 2026. doi:10.1111/exd.70350
BibTeX
@article{Xue2026,
author = {Xue, Shumeng and Shen, Yuanxing and Zhang, Chong and Ye, Qian and Zhang, Yi and Xu, Haoxiang and He, Yanyan},
title = {Nicastrin Regulates Cutaneous Squamous Cell Carcinoma Progression Through the MAPK / ERK Signalling},
journal = {Experimental Dermatology},
year = {2026},
doi = {10.1111/exd.70350}
}
EUVIMED